Maintaining confidentiality of interim data to enhance trial integrity and credibility

Clinical Trials

Volumn 5, Issue 2, 2008, Pages 157-167

  Fleming, Thomas R ^a   Sharpies, Katrina ^b   McCall, John ^c   Moore, Andrew ^d   Rodgers, Anthony ^c   Stewart, Ralph ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; DIDANOSINE; FLUOROURACIL; GANCICLOVIR; INTERFERON BETA SERINE; LEVAMISOLE; NAPROXEN; PLACEBO; SORAFENIB; VALSARTAN; ZALCITABINE;

ALZHEIMER DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFIDENTIALITY; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DRUG SAFETY; EVIDENCE BASED PRACTICE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; MONOTHERAPY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; RISK BENEFIT ANALYSIS; STROKE;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; CONFIDENTIALITY; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; HUMANS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 43649105816     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774508089459     Document Type: Review

References (34)

1. Ellenberg SS, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective. John Wiley & Sons, Ltd., Chichester, West Sussex, England, 2002.
2. Grant AM, Altman DG, Babiker AB, et al. Damocles study group. Issues in data monitoritng and interim analyses of trials. Health Technology Assessment (Winchester, England). 2005: 9.
3. National Institutes of Health. Policy for Data and Safety Monitoring. http://grants.nih.gov/grants/guide/notice-files/not98-084.html (accessed 19 February 2007).
4. World Health Organisation. Operational Guidelines for the Establishment and Functioning of Data and Safety Monitoring Boards. http://www.who.int/tdr/publications/publications/pdf/operat_guidelines.pdf (accessed 19 February 2007).
5. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Data Monitoring Committees. http://www.emea.eu.int/pdfs/ human/ewp/587203en.pdf (accessed 19 February 2007).
6. FDA. Guidance for clinical trial sponsors: On the establishment and operation of clinical trial data monitoring committees. http://www.fda.gov/ OHRMS/DOCKETS/98fr/old-0489-gdl0003.pdf (accessed 19 February 2007).
7. Weeks JC, Nelson HN, Gelber S, et al. for the Clinical Outcomes of Surgical Therapy (COST) Study Group. Short term quality-of-life outcomes following laparoscopic-assisted versus open colectomy for colon cancer. JAMA 2002; 287: 321-28.
8. Guillou PJ, Quirke P, Thorpe H, et al. for the MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomized controlled trial. Lancet 2005; 365: 1718-26.
9. The COLon cancer Laparoscopic or Open Resection Study Group. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomized trial. Lancet Oncol 2005; 6: 477-84.
10. Australasian Laparoscopic Colon Cancer Study. http://clinicaltrials.gov/ ct/show/NCT00202111 (accessed 19 February 2007).
11. Fleming TR. Surrogate endpoints and FDA's accelerated approval process: The challenges are greater than they seem. Health Affairs 2005; 24: 67-78.
12. Armitage P, McPherson CK, Rowe BC. Repeated significance tests on accumulating data. Journal of the Royal Statistical Society, Series A 1969; 132: 235-44.
13. McPherson K. Statistics: the problem of examining accumulating data more than once. New England Journal of Medicine 1974; 290: 501-02.
14. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. British Journal of Radiology 1971; 44: 793-97.
15. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191-99.
16. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
17. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clinical Trials 1984; 5: 348-61.
18. Grant AM, Altman DG, Babiker AB, et al. DAMOCLES Study Group. Issues in data monitoring and interim analyses of trials. Health Technology Assessment (Winchester, England). 2005; 9: 25.
19. Green SJ, Fleming TR, O'Fallon JR. Policies for study monitoring and interim reporting of results. Journal of Clinical Oncology 1987; 5: 2477-484.
20. Rider WD, Palmer JA, Mahoney LJ, Robertson CT. Preoperative irradiation in operable cancer of the rectum: Report of the Toronto trial. Canadian Journal of Surgery 1977; 20: 335-38.
21. Medical Research Council Working Party. The evaluation of low-dose preoperative x-ray therapy in the management of operable rectal cancer: results of a randomly controlled trial. British Journal of Surgery 1984; 71: 21-25.
22. Escudier B, Eisen T, Stadler WM, et al. for the TARGET Study Group, Sorafenib in advanced clear-cell renal cell carcinoma. New England Journal of Medicine 2007; 356: 125-34.
23. Abrams D, Goldman A, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. New England Journal of Medicine 1994; 330: 657-62.
24. Korn EL, Hunsberger S, Freidlin B, et al. Preliminary data release for randomized clinical trials of noninferiority: a new proposal. Journal of Clinical Oncology 2005; 23: 5831-36.
25. Julius S, Kjeldsen SE, Weber M, et al. The VALUE trial group, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
26. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized controlled Alzheimer's disease anti-inflammatory prevention trial (ADAPT). PLoS Clinical Trials 2006; 1: e 33.
27. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large bowel carcinoma: An evaluation of levamisole and the combination of leucovorin and fluorouracil. J Clin Oncol 1989; 7: 1447-56.
28. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New England Journal of Medicine 1990; 322: 352-58.
29. Spector SA, McKinley GF, Collins G, et al. Oral gancyclovir for the prevention of cytomegalovirus disease in patients with AIDS. New England Journal of Medicine 1996; 334: 1491-97.
30. Brosgart CL, Louis TA, Hillman DW, et al. A randomized placebo-controlled trial of the safety and efficacy of oral gancyclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beim Community Programs for Clinical Research on AIDS. AIDS 1998; 12: 269-77.
31. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of Interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.
32. The North American Study Group on Interferon β-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Neurology 2004; 63: 1788-95.
33. Grant AM, Altman DG, Babiker AB, et al. Damocles Study Group. Issues in data monitoring and interim analyses of trials. Health Technology Assessment (Winchester, England) 2005; 9: 24.
34. Lilford RJ, Braunholtz D, Edwards S, et al. Monitoring clinical trials: interim data should be publicly available. British Medical Journal 2001; 323: 441-42.